The 8 highest-scored Biopharmaceutical - Oncology companies in the AskCyborg corpus, ranked by Cyborg Score — a 1–10 rating from a bull-vs-bear AI analyst debate across 11 dimensions. Leading the table: Syndax Pharmaceuticals, Inc. (8/10), Puma Biotechnology, Inc. (7/10), Zai Lab Limited (7/10).
| # | Company | Cyborg Score | The verdict | Ownership | Peers |
|---|---|---|---|---|---|
| 1 | Syndax Pharmaceuticals, Inc. | 8/10 | Compelling first-to-market menin inhibitor with expanding indications and strong market traction offset by pre-profitability and execution r | Public | |
| 2 | Puma Biotechnology, Inc. | 7/10 | Profitable, single-product biotech with strong NERLYNX commercial traction and pipeline hope from alisertib trials offering modest upside wi | Public | |
| 3 | Zai Lab Limited | 7/10 | Zai Lab is transitioning from a profitable China-focused operator to a globally competitive biopharmaceutical company with late-stage oncolo | Public | |
| 4 | Genenta Science | 6/10 | Specialized neoantigen immunotherapy platform with meaningful clinical potential, balanced against execution risks inherent to early-stage o | Public | |
| 5 | BioAtla, Inc. | 4/10 | High-risk clinical-stage biotech with differentiated CAB technology platform and advancing pipeline, but acute financial constraints and exe | Public | |
| 6 | Mersana Therapeutics, Inc. | 4/10 | Acquired for its novel B7-H4-targeting ADC pipeline addressing unmet oncology needs, particularly adenoid cystic carcinoma. | Public | |
| 7 | Propanc Biopharma, Inc. | 4/10 | High-risk early-stage biotech with novel mechanism, limited analyst coverage, and cash constraints typical of pre-clinical/clinical stage on | Public | |
| 8 | MacroGenics, Inc. | 3/10 | While analysts suggest moderate buy potential with a $3.4 target price, execution risks and regulatory setbacks present high clinical and fi | Public |
See also Biopharmaceutical - Oncology industry research and the full industry ratings index.
Cyborg Scores (1–10) are synthesized by AskCyborg’s multi-agent analyst-debate framework across 11 dimensions, recalibrated weekly. How the score works · Methodology.